Last-Resort drug made available for rare lung infections
NCT ID NCT04334070
First seen Jan 11, 2026 · Last updated May 05, 2026 · Updated 16 times
Summary
This program provides Lamprene (clofazimine), a drug originally approved for leprosy, to adults with non-tuberculous mycobacterial (NTM) infections who have no other treatment options. Patients must be 18 or older and have failed or cannot tolerate standard therapies. The drug is given under a special expanded access program because it is not FDA-approved for NTM.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-TUBERCULOUS MYCOBACTERIAL (NTM) INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.